pharmaphorum
FEBRUARY 9, 2022
In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. According to a report by IQVIA last year, there were 3,500 oncology-focused therapeutic candidates in the pipeline, which represents a 75% increase on figures seen in 2015.
NY Times
FEBRUARY 8, 2022
A crucial Johnson & Johnson plant has stopped making its Covid vaccine, though the company says it has millions of doses in inventory.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
FEBRUARY 7, 2022
The HIV-focused pharma company announced the agency has approved Cabenuva for administration as few as six times a year for adults living with the virus.
Pharma Marketing Network
FEBRUARY 10, 2022
Experts from top life sciences companies discussed strategies for more effectively engaging oncologists at the Pharma Marketing Network’s 2022 Future Forecast on January 25 th. Here are the top three things to know about engaging oncologists in 2022: 1. Lead with clinical education. It’s no longer enough to build brand awareness, according to the panelists.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
FEBRUARY 8, 2022
Novo Nordisk’s new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE, but in a narrower group of patients than is covered by its MHRA-approved label. NICE has backed use of the Wegovy (semaglutide) for people with a body mass index (BMI) of 35 kg/m2 or more and at least one weight-related ailment – such as high blood pressure, high cholesterol or diabetes – as part of a weight management programme involving exercise and a reduce-calorie
Pharma Times
FEBRUARY 11, 2022
Rare viral haemorrhagic disease similar to Ebola surface in the East of England
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
NY Times
FEBRUARY 11, 2022
The agency will wait for data on whether three doses of Pfizer-BioNTech’s Covid vaccine are effective in young children after new, disappointing data.
pharmaphorum
FEBRUARY 9, 2022
The digitalisation that we all experience daily has affected the way we engage with stakeholders and patients. But how can we make Customer Engagement effective, and how can we leverage technologies like AI and Marketing Automation to their best potential? The key to success lies in implementing a digital health ecosystem , in order to support the shift from an organization-centric model to a customer-centric model by using digital platforms.
Pharma Times
FEBRUARY 7, 2022
Institute for Cancer Research highlights missed opportunity for NICE to reform its cancer drug assessment processes
Outsourcing Pharma
FEBRUARY 9, 2022
The companyâs analysis of trials conducted around the world last year shows cancers took four of the top five positions, with COVID-19 in second place.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Channels
FEBRUARY 11, 2022
Today’s guest post comes from John Beardsley, Senior Vice President of Corporate Strategy at CoverMyMeds. John discusses some of the findings in CoverMyMeds’ recently published report on medication access. He describes patient-centric, data-driven solutions to help patients access, afford, and adhere to their therapies. To learn more, download CoverMyMeds’ 2022 Medication Access Report.
pharmaphorum
FEBRUARY 10, 2022
With staff shortages and digital skill gaps being experienced across the spectrum of healthcare, from CROs and pharma to providers, the people-led sector is facing a personnel challenge that could threaten the potential of digital transformation. The healthcare ecosystem may be the natural beneficiary of recent advances in data collection and analysis, but that’s no use without the staff to develop and implement solutions.
Pharma Times
FEBRUARY 9, 2022
Sustainable lateral flow test kits developed in Birmingham reduce plastic and boost self-testing through ease of use
NY Times
FEBRUARY 10, 2022
Pharmacists and technicians, who have played a critical role in administering Covid-19 tests and vaccines, say they are burned out nearly two years into the pandemic.
Outsourcing Pharma
FEBRUARY 10, 2022
In the first of a two-part series, leaders from the CRO discuss how study data has progressed in recent years and how trial teams can keep up effectively.
pharmaphorum
FEBRUARY 8, 2022
Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty. The massive windfall revenues will drive its sales up towards the $100 billion mark – it’s estimating a range of $98 to $102 billion – up from $81.3 billion in 2021, which was almost twice revenues in the prior year.
Pharma Times
FEBRUARY 10, 2022
Research demonstrates that people who live with peanut allergies face isolation and discrimination
NY Times
FEBRUARY 10, 2022
The agency threw out previous recommended limits on doses but encouraged “nonopioid therapies” wherever possible.
Drug Channels
FEBRUARY 7, 2022
Drug Pricing Transparency Congress. Hybrid Event March 28-29, 2022 | Philadelphia, PA www.informaconnect.com/drug-pricing-transparency. Don’t miss the Drug Pricing Transparency Congress on March 28-29, 2022! You'll be part of the important discussions on how current and future drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices.
pharmaphorum
FEBRUARY 10, 2022
The FDA has granted fast-track status to Bayer’s oral Factor Xia inhibitor asundexian, which is in phase 2 testing as an anticoagulant that could offer safety advantages over current drugs. Asundexian (also known as BAY2433334) will be given a speedy review by the US regulator as a secondary preventative treatment for people with ischaemic stroke, specifically those with non- cardioembolic risk factors like narrowed arteries.
Pharma Times
FEBRUARY 8, 2022
NICE recommends appetite suppressing drug which can reduce a patient’s by more than 10%
NY Times
FEBRUARY 9, 2022
It’s not clear whether three doses of the Pfizer-BioNTech vaccine will adequately protect young children. But the F.D.A. may authorize the first two doses anyway.
Outsourcing Pharma
FEBRUARY 10, 2022
The pharmaceutical company, which uses thin-film freezing to develop inhalable therapies, has completed enrollment in the first phase for its drug candidate.
pharmaphorum
FEBRUARY 11, 2022
Komodo Health’s president and co-founder, Web Sun, tells us about his company’s new partnership with the Chan Zuckerberg Initiative (CZI) to improve early diagnosis and advance research of rare diseases by providing CZI’s Rare as One Network healthcare data and software. Though 7,000 rare diseases exist that affect 400 million people globally, a lack of understanding of these diseases can cause a delay in diagnosis and, in turn, treatment.
Pharma Times
FEBRUARY 7, 2022
Extensive research into pharmacy responses across Europe during the pandemic yields several recommendations
NY Times
FEBRUARY 11, 2022
The federal government has ordered 600,000 doses of the monoclonal antibody treatment, which is meant for high-risk Covid patients early in their illness.
Drug Channels
FEBRUARY 8, 2022
More than four years ago, I warned about the emerging trend of copay accumulators and outlined the costly consequences for patients. The latest data reveal that copay accumulator adjustment programs are now in the word list for a growing share of pharmacy benefit designs. What’s more, adoption of copay maximizers now exceeds that of copay accumulators.
pharmaphorum
FEBRUARY 9, 2022
GlaxoSmithKline’s COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive Emma Walmsley says will be a “landmark year” for the company. Xevudy (sotrovimab), which was developed with Vir Biotech and has seen its use rise after it was shown to be effective against the Omicron strain of SARS-CoV-2, brought in £958 million, £828 million of that in the last quarter of th
Pharma Times
FEBRUARY 8, 2022
Greater urgency for kidney cancer treatments as 40% of UK patients wait 84 days for a diagnosis
NY Times
FEBRUARY 10, 2022
The panel debated whether overseas trials could be applied to a more diverse U.S. population. The decision may affect other Chinese drug trials, and spotlights the high cost of immunotherapy.
Drug Patent Watch
FEBRUARY 10, 2022
Annual Drug Patent Expirations for SYMBICORT Symbicort is a drug marketed by Astrazeneca and is included in one NDA. It is available from three suppliers. There are ten patents protecting…. The post New patent expiration for Astrazeneca drug SYMBICORT appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
FEBRUARY 10, 2022
Amazon has passed another milestone in the rollout of its healthcare business, makings it telehealth service available nationwide in the US and adding another 20 cities to its in-person services. The online retail giant first started offering the Amazon Care service to some of its own employees in 2019, expanding it to all its US workforce in 2021 and offering it to other organisations, including recently the Hilton hotel chain.
Pharma Times
FEBRUARY 10, 2022
Diurnal’s pioneering phase 2 study evaluates modified-release hydrocortisone for adrenal insufficiency
NY Times
FEBRUARY 11, 2022
No está claro si tres dosis de la vacuna Pfizer-BioNTech protegerán adecuadamente a los niños. Pero es posible que la FDA autorice las primeras dos dosis de cualquier manera.
Drug Patent Watch
FEBRUARY 10, 2022
Annual Drug Patent Expirations for BARHEMSYS Barhemsys is a drug marketed by Acacia and is included in one NDA. There are four patents protecting this drug. This drug has thirty-eight…. The post New patent for Acacia drug BARHEMSYS appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
125 
Let's personalize your content